Efficacy and safety of ipragliflozin as add‐on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi‐centre, randomized, placebo‐controlled, double‐blind study

समान संसाधन

• Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study
  द्वारा: Ishihara, Hisamitsu, और अन्य
  प्रकाशित: (2018)
• Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
  द्वारा: Ishihara, Hisamitsu, और अन्य
  प्रकाशित: (2018)
• Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
  द्वारा: Ishihara, Hisamitsu, और अन्य
  प्रकाशित: (2019)
• Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
  द्वारा: Kaku, Kohei, और अन्य
  प्रकाशित: (2019)
• Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
  द्वारा: Kashiwagi, A, और अन्य
  प्रकाशित: (2015)